title: Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
abstract: BACKGROUND
  A number of studies have shown that absence of myelotoxicity during chemotherapy is associated with worse outcome for various types of cancer, including carcinoma of the breast. The aim of this study was to determine whether myelosuppression in patients being treated with chemotherapy for advanced breast cancer has an impact on their prognosis.
  
  
  METHODS
  A retrospective review was conducted of a series of 475 patients with advanced breast cancer enrolled in two randomised trials, who received first-line chemotherapy. The impact of severe (grade 3 or 4) hematological toxicity on survival and time to disease progression was assessed.
  
  
  RESULTS
  When severe myelotoxicity was evaluated as a whole, a significant negative association for time to disease progression and a trend for a worse survival were demonstrated. In multivariate analysis, hematological toxicity retained its significance as an independent negative prognostic factor for time to disease progression.
  
  
  CONCLUSIONS
  Our findings do not confirm the results of previous studies which have demonstrated a better outcome for patients experiencing hematological toxicity during treatment.
authors.affiliation: Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, Greece. angkoutr@otenet.gr
authors.forename: Angelos K
authors.initials: AK
authors.lastname: Koutras
authors.forename: George
authors.initials: G
authors.lastname: Fountzilas
authors.forename: Urania
authors.initials: U
authors.lastname: Dafni
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Pectasides
authors.forename: George
authors.initials: G
authors.lastname: Klouvas
authors.forename: Pavlos
authors.initials: P
authors.lastname: Papakostas
authors.forename: Paris
authors.initials: P
authors.lastname: Kosmidis
authors.forename: Epaminondas
authors.initials: E
authors.lastname: Samantas
authors.forename: Helen
authors.initials: H
authors.lastname: Gogas
authors.forename: Evangelos
authors.initials: E
authors.lastname: Briasoulis
authors.forename: Georgia
authors.initials: G
authors.lastname: Vourli
authors.forename: Theodoros
authors.initials: T
authors.lastname: Petsas
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Xiros
authors.forename: Haralabos P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D015251:Epirubicin; D016190:Carboplatin; D017239:Paclitaxel